A prospective registry study of 336 consecutive transcatheter aortic valve replacement (TAVR) patients with heart failure and reduced ejection fraction (HFrEF) reveals stark gaps in applying guideline-directed medical therapy (HF-GDMT) and its powerful impact on outcomes. 
In the study published in the JAC: Cardiovascular Interventions, the researchers grouped patients by medications prescribed at hospital discharge and again after three months of optimization: quadruple therapy (15% at discharge, 27% at three months), triple (19% to 21%), double (28% to 21%), or single/no therapy (38% to 27%). Among 280 eligible for the full quadruple combo—typically ARNI/ACEI/ARB, beta-blocker, MRA, and SGLT2 inhibitor—only 27% actually received it by three months. Over a median 699-day follow-up, they tracked major adverse cardiovascular events (MACE), combining cardiovascular death or heart failure hospitalization.
Quadruple Therapy Rare Despite Clear Eligibility
At discharge, just 15% hit quadruple HF-GDMT, climbing modestly to 27% after three months of tweaks, leaving most on weaker regimens. Triple and double therapy hovered around 20-28%, while 27% ended with single drug or none. This underuse persists despite HFrEF guidelines urging full stacks post-TAVR, where valve fixes address aortic stenosis but leave systolic dysfunction demanding aggressive medications. Cardiologists will recognize familiar hurdles like renal function, blood pressure drops, or oversight in procedural recovery focus.
Strongest Therapy Slashes Two-Year Events
After three-month optimization, two-year MACE rates dropped sharply by therapy intensity: 15.0% (95% CI: 5.2%-24.8%) for quadruple versus 22.6% (10.4%-34.8%) triple, 24.2% (13.8%-34.6%) double, and 43.6% (31.8%-55.4%) for single/no therapy (log-rank P<0.001). Full therapy halved rehospitalizations and deaths compared to minimal care, proving GDMT amplifies TAVR's valve benefits in weak-heart cases. Patients on quadruple saw sustained gains over nearly two years, underscoring medications' role beyond structural fixes.
Optimization Window Reveals True Gaps
The three-month checkpoint highlighted how initial discharge plans often fall short, with only a quarter of eligible patients reaching gold-standard combos. Proceduralists and heart failure specialists share responsibility here, as TAVR recovery offers prime titration time before discharge home. Suboptimal therapy linked directly to worse events, suggesting intolerance or inertia drives risks that full GDMT could avert.
Urgent Push for Better Post-TAVR Heart Care
These data demand systematic changes: checklists for GDMT at discharge, dedicated optimization clinics, and team training to hit quadruple therapy in HFrEF-TAVR cases. With 83% eligibility unmet, simple protocols could prevent thousands of events yearly. Interventionalists gain ammunition to collaborate with HF teams, turning TAVR success into lasting survival wins through medicationss.